









































































N/L ratio Neutrophil to Lymphocyte ratio 
PCV 
RBC 
Packed Cell Volume 
Red Blood Cell 
SAA Serum Amyloid A 
SD Standard Deviation 
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K-4500 White Blood Cell WBC
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Table 1. Mean ± SD values for variables evaluated in 32 healthy Thoroughbreds that received 
enrofloxacin (5 mg/kg, IV, once; enrofloxacin group) or saline (0.9 % NaCl) solution (50 mL, 
IV, once; control -distance transportation (duration, approx 26 
hours). 
Before After Before After
Variable transportation transportation transportation transportation
Body weight (kg) 492.4 ± 27.2 477.3 ± 25.7 488.4 ± 24.9 470.9 ± 24.0
Rectal temperature ( ) 38.1 ± 0.3 38.0 ± 0.2a 37.9 ± 0.2 38.5 ± 0.4b
Peripheral blood
WBC count (No./mm3) 8,150 ± 965 8,225 ± 904c 8,294 ± 1,722 10,825 ± 2,256d
N/L Ratio 1.5 ± 0.5 1.6 ± 0.4c 1.5 ± 0.7 4.3 ± 2.8d
0.2 ± 0.2 0.6 ± 1.6c 0.1 ± 0.1 63.4 ± 82.6d
PCV (%) 39.5 ± 3.5 42.3 ± 2.8 39.5 ± 2.5 41.3 ± 3.7
Hgb concentration (g/dL) 13.6 ± 1.2 14.6 ± 1.0 13.5 ± 0.9 14.1 ± 1.4
TBA
WBC count (X 105/mL) 1.3 ± 0.5 1.3 ± 0.5c 1.3 ± 0.5 14.5 ± 11.1d
Neutrophils (%) 2.7 ± 1.2 2.8 ± 1.0c 2.5 ± 0.8 67.0 ± 47.3d
Group
Enrofloxacin (n = 16) Control (n = 16)
All horses were premedicated with interferon- transportation and 
on the day of transportation). 
a,bWithin a row, values with different superscript letters are significantly (p < 0.05) different. 
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Table 2. Rectal temperatures and blood parameters before and after transportation in horses 




















































































Data are expressed as the median (range). 
A,B Values with the same superscript letters are significantly (p<0.01) different according to 
the Mann-Whitney U-test. 
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Table 3-1. Rectal temperatures and blood parameters before and after transportation in horses 
dosed prophylactically with IFN-
WBC
(/mm3)























































Data are expressed as the mean ± SD.
*Significant difference as compared with the control group (p < 0.05). 
38 
Table 3-2. Numbers of febrile horses distributed according to rectal temperature during and 
after transportation. 
< 38.5 > 38.5 > 39.1
Control 10 4 (3A, 1B ) 2 (2B )
MRFX 12 4 (2A) 0
ERFX 13 2 (1A) 1 (1A)
Group
Rectal temperature (°C)
A Number of horses administered penicillin-streptomycin combination. 
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Table 4-1 2008 2012 2013
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2012 56 2013
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Table 4-1. Horse groups investigated 
Male Female Total
2007 Hokkaido Hyogo 1,540 36 24 26 50
2008 Hokkaido Chiba 1,210 26 25 24 49
2012 Hokkaido Chiba 1,210 26 27 29 56










MRFX = marbofloxacin 
- : not administrated, + : administrated 
47 
Table 4-2. Changes of rectal temperature before and after transportation 
Before transportation After transportation
2007 50 38.0 ± 0.22 38.5 ± 0.40a
2008 49 37.9 ± 0.16 38.6 ± 0.42b
2012 56 37.9 ± 0.18 38.3 ± 0.26b






MRFX = marbofloxacin 
 : not administrated,  : administrated 
a,bWithin a row, values with same superscript letters are significantly (p < 0.01) different. 
Data are expressed mean ± SD.
48 
Table 4-3. Treatment after transportation 
Not febrile Febrile
2007 - 2008 99 80 19 (14A, 5B)




MRFX = marbofloxacin 
ANumber of horses administered penicillin-streptomycin combination. 
BNumber of horses administered cephalothin sodium. 
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G-CSF 4 4 429 ± 22 kg 3 5
421 ± 25 kg 2
G-CSF 0.23 µg/kg BS 300 µg
0.3 ml
6
3 0.15 µg/kg 0.23 µg/kg 0.31 µg/kg
0.23 µg/kg 1 2
6 0.23 
µg/kg 3,185 ± 914 /mm3
5,702 ± 914 /mm3 2 4,902 ± 1,128 /mm3 ±
SD 1
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Table 5-1 48 hr G-CSF 38.6 ºC
38.0-39.0 38.6 ºC 38.0 39.0 °C
48 hr WBC /
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Table 5-1. Rectal temperatures and blood parameters before and after transportation in horses 
dosed prophylactically with filgrastim 
WBC
(/mm3)













































































Data are expressed as the median (range). 
a,b,c Values with the same superscript letters are significantly (p<0.05) different according to 
the Steel-Dwass test. 
D Values with the same superscript letters are significantly (p<0.01) different according to 
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Transportation-associated fever is mainly caused by the infection of the bronchoalveolar 
regions with S. zooepidemicus that is resident in the tonsillar tissues and trachea of healthy 
horses. A decrease in the incidence of fever associated with transportation and improvement 
in clinical condition was reported for horses orally administered IFN-  for 3 consecutive days 
before transportation to activate the immune system.  However, this protocol did not 
completely prevent fever associated with transportation, so further prophylactic measures are 
needed. In contrast, new broad-spectrum quinolone antibiotics have been used clinically as 
long-acting antimicrobial agents, including for treatment of infections of the respiratory 
system.  However, there are, to our knowledge, no previous reports of the administration of 
new broad-spectrum quinolone antibiotics for the prevention of fever associated with 
transportation. 
Regarding the use of an antimicrobial agent, there is the problem of onset of resistant 
bacteria. On the other hand, it is known that the G-CSF promotes granulocytic growth in 
marrow and mobilization to peripheral blood. According to a previous investigation, serum 
G-CSF was significantly high in horses that developed transportation-associated fever.  
Therefore, an increase level of G-CSF represents one of the natural healing responses and is 
thought to be a condition suitable for exclusion of S. zooepidemicus.  However, there are, to 
our knowledge, no previous reports of the effect of a G-CSF formulation during transportation.
Therefore, we performed the following five studies to investigate the effectiveness of 
pre-shipping ERFX, MRFX and G-CSF administration on fever and blood properties in 
healthy Thoroughbreds transported a long distance. 
In the first study, we evaluated the effects of single-dose enrofloxacin in protecting horses 
against fever associated with transportation using 32 healthy Thoroughbreds.  All horses 
were premedicated with IFN-
70 
transportation. Post-transportation rectal temperature, WBC count, N/L ratio and SAA in the 
peripheral blood, together with WBC count and percentage of neutrophils in TBAs were 
significantly lower in horses in the ERFX group compared with the control horses.  It 
suggested that ERFX conspicuously decreased number of organisms of S. zooepidemicus
which is main reason bacteria of the shipping fever and, as a result, it relieved the invasion 
into lower respiratory tracts of S. zooepidemicus. These results show that prophylactic ERFX 
administration with IFN-  just before transportation was clinically effective at preventing 
transportation-associated fever. 
In the second study, in order to reveal the preventive effect of ERFX administration without 
IFN-  just before transportation, we compared 68 adult Thoroughbred racehorses. 
Post-transportation rectal temperature, WBC count and SAA in the peripheral blood were 
significantly lower in horses in the ERFX group compared with the control horses.  
Furthermore, the result that cortisol in the ERFX group was significantly lower was 
considered that ERFX decreases the stress of transported horses by relieving the invasion by S. 
zooepidemicus.We have demonstrated that the prophylactic ERFX administration without 
IFN-  just before transportation is clinically effective at preventing transportation-associated 
fever in adult Thoroughbred racehorses in the same way as 2YO young Thoroughbreds. 
In the third study, we evaluated the effects of single-dose MRFX in protecting horses 
against fever associated with transportation using 48 healthy Thoroughbreds.  All horses 
were premedicated with IFN-  for 2 days before transportation and on the day of 
transportation. Post-transportation N/L ratios were significantly lower in horses in the MRFX 
group compared with the control horses.  The SAA levels were significantly lower in horses 
in the MRFX group and ERFX group compared with the control horses. It suggested that 
MRFX conspicuously decreased number of organisms of S. zooepidemicus which is main 
71 
reason bacteria of the shipping fever and, as a result, it relieved the invasion into lower 
respiratory tracts of S. zooepidemicus. Therefore, it was shown that MRFX had efficacy in the 
inflammatory reaction suppression after the transportation. 
In the fourth study, in order to reveal the preventive effect of MRFX administration just 
before transportation, we compared the occurrence of transportation-associated fever before 
and after introduction of MRFX administration. No horses were premedicated with IFN- . 
After the introduction of prophylactic MRFX administration, the rectal temperatures of horses 
after transportation were significantly lower than before the introduction of MRFX 
administration and the number of febrile horses was significantly lower than before the 
introduction of MRFX administration. These results show that prophylactic MRFX 
administration alone just before transportation was clinically effective at preventing 
transportation-associated fever. 
In the fifth study, we evaluated the effects of single-dose filgrastim on hematology in 16 
healthy horses after long-distance transportation. Because the post-transportation WBC counts 
and bacillary neutrophil to segmented neutrophil ratio were significantly higher in the G-CSF 
group, filgrastim may have promoted the mobilization of neutrophils from marrow.  It 
suggests that administration of filgrastim just before transportation activates natural immunity 
for more than 48 hours and can protect against invasion by S. zooepidemicus. Therefore, it 
was shown that G-CSF had efficacy in activating natural immunity during transportation. 
Based on the results of the five studies, it was demonstrated that prophylactic EFRX and 
MRFX administration each alone just before transportation was clinically effective at 
preventing transportation-associated fever. And, it was shown that G-CSF had efficacy in 
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